Arcadia Biosciences (NASDAQ:RKDA) Issues Earnings Results, Misses Estimates By $1.31 EPS

Arcadia Biosciences (NASDAQ:RKDA) released its quarterly earnings data on Thursday. The basic materials company reported ($2.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($1.31), FiscalAI reports. Arcadia Biosciences had a positive return on equity of 37.36% and a negative net margin of 48.15%.The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.60 million.

Arcadia Biosciences Trading Up 0.9%

RKDA opened at $1.07 on Friday. The stock has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.62 and a beta of 0.52. Arcadia Biosciences has a 1-year low of $0.89 and a 1-year high of $6.71. The business has a 50 day moving average of $1.41 and a 200-day moving average of $2.33.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Arcadia Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.